Acquisitions of laboratories, imaging and dialysis centers declined in 2016, as each of the sectors faced headwinds.
Mallinckrodt is just one of many big-name pharma companies that are divesting non-core businesses in order to target specific therapeutics and disease areas.
Some large and small healthcare players are shifting their portfolios to focus on the hemostasis analyzer market, which is expected to reach nearly $5 billion by 2021.
You can’t get much more “specialty” in the specialty pharmacy business than to deal in radiopharmaceuticals. Two recent deals, announced in August, show this area is heating up. IBA Molecular, a global maker and distributor of radiopharmaceutical products, agreed to pay approximately $613 million for Mallinckrodt‘s (NYSE: MNK) nuclear imaging business, including a portfolio of […]
Last week’s Biggest Deal was Mallinckrodt plc’s (NYSE: MNK) $1.325 billion acquisition of Therakos, Inc., an immunotherapy company, from The Gores Group. Gores acquired Therakos back in October 2012 for an undisclosed price from Ortho-Clinical Diagnostics. The transaction is expected to be accretive by no less than $0.10 per share to Mallinckrodt’s adjusted diluted fiscal […]
Last week we noted that April was a slow month for healthcare deals. Then we checked our database, DealSearchOnline.com, and discovered there have been 19 billion-dollar deal announcements already in 2015, through May 8th, with a combined total of $103.6 billion. The total for the entire year is about to top $120 billion, on 487 […]
Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.